STUDresearch · Peptide
GHRH (1-44)
Also known as
Somatorelin · Growth hormone–releasing hormone (1-44) · hGHRH(1-44) · hGHRH(1-44)NH2 · GHRH-1,44-amide · GRF (1-44) · Growth hormone–releasing factor (1-44) · Somatocrinin (endogenous form discussions) · GHRH 1-44 amide · somatotropin releasing hormone (1-44)amide · Full-length GHRH
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
IV / SubQ
Growth hormone axis
Systemic — binds pituitary GHRH receptors and raises endogenous GH pulses (then IGF-1); not a local repair or site-specific fat-dissolve peptide.
What people say
GHRH(1–44) is full-length human growth-hormone-releasing hormone. It triggers pituitary GH release but is not hGH, sermorelin, tesamorelin, CJC or a ghrelin-receptor GHRP.
Doses people talk about
Route and molecule matter. An IV stimulation test, continuous SC research infusion and sermorelin forum amount are not interchangeable regimens.
How it may feel
Supervised IV testing can cause brief flushing or warmth. Dedicated unmodified-1–44 lifestyle reports are scarce; sleep, energy and body-composition stories online usually concern sermorelin, tesamorelin or CJC instead.
Borrowed analogue forum band~100–500 mcg SC nightly
Sermorelin 1–29 discussion, often 200–300 mcg; included to show what forums mean by “GHRH,” not as native 1–44 evidence.
Diagnostic native 1–44~1 µg/kg IV once
Supervised stimulation-test context with serial blood draws, not lifestyle use or a repeated community cycle.
Older native 1–44 research1 or 2 mg/day continuous SC
Fourteen-day crossover infusions in healthy old men, with a 14-day treatment-free interval; not a bolus or forum microdose.
Older postmenopausal study1 mg SC twice daily
Three-month recombinant hGHRH(1–44)-amide research; high local-reactivity rate and no equivalence to consumer analog charts.
Half-life & effect duration
- Half-life in the body
- Intact peptide · IVAbout 6.8 minutes
- Intact peptide · plasma testAbout 17 minutes
- Felt duration people report
- Around IV useBrief flushing or warmth
- Other felt effectsNo consistent GHRH 1–44-specific duration reported
Cycles people discuss
Contexts differ: a one-session diagnostic test, 14-day continuous SC research infusions and about 90-day high-dose studies. Forum 5-on/2-off calendars usually belong to analogs, not native 1–44.
Timing
Bedtime/pre-sleep SubQ and post-meal spacing are borrowed from broader GHRH discussions, not established native-1–44 lifestyle timing. Published milligram research also used twice-daily SubQ dosing, separate from the borrowed nightly microgram charts.
Stacks
Modern community GHRH/GHRP stacks usually name sermorelin or CJC with ipamorelin, GHRP-2 or GHRP-6. That class discussion does not prove unmodified 1–44 use or equivalence.
Watch for
Local skin reactivity (high-dose chronic SC): In the 1 mg BID × 3-month postmenopausal study, ~70% of subjects had local skin reactivity; no systemic adverse events were reported in that small open study — still a major practical tolerability flag at research milligram doses.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Intact IV GRH(1–44)-NH2 had a measured 6.8-minute plasma half-life.
The same work found a 17-minute intact-parent half-time in human plasma in vitro, while total RIA immunoreactivity persisted about 63 minutes because GRH(3–44) remained detectable.
IV normal-subject result; not SC kinetics, endogenous portal secretion, 1–29 fragments, tesamorelin, CJC or duration of GH/IGF-1 effects.
- Frohman et al. — Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo (opens in a new tab)Abstract and full text: intact GRH(1–44)-NH2 measured by HPLC; 17-minute half-time in human plasma in vitro and 6.8-minute half-life after IV injection in normal subjects; GRH(3–44) retained RIA signal but less than 10^-3 activity.Classic small mechanistic study; IV and in-vitro results do not define SC bioavailability, community product identity or subjective duration.
Felt duration people report
A dependable felt duration for unmodified GHRH(1–44) was not established.
Brief flushing or warmth is described around diagnostic IV use. Online sleep, energy and body-composition accounts overwhelmingly concern sermorelin, CJC or tesamorelin and cannot be reassigned to 1–44.
Sparse molecule-specific self-reports; analogs differ in sequence and stability; longer GH/IGF-1 endpoints are not parent-peptide felt duration.
- Frohman et al. — Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo (opens in a new tab)Abstract and full text: intact GRH(1–44)-NH2 measured by HPLC; 17-minute half-time in human plasma in vitro and 6.8-minute half-life after IV injection in normal subjects; GRH(3–44) retained RIA signal but less than 10^-3 activity.Classic small mechanistic study; IV and in-vitro results do not define SC bioavailability, community product identity or subjective duration.
- Overview of HGH secretagogues — community GHRH/GHRP discussion (opens in a new tab)Full visible thread and replies: discussion names sermorelin, Mod GRF, CJC, tesamorelin and GHRPs, repeated 100 mcg and 5-on/2-off claims, and reports of inconsistent itching/redness. It does not provide a dedicated unmodified 1–44 experience.Long mixed-quality forum thread with unsupported class generalizations and no verified products. Advice and preparation material were not adopted; absence of 1–44 reports is limited to visible content.
- My Sermorelin Experience (opens in a new tab)Original post and visible replies: author described changes over 2–4.5 months; replies included opposite sleep responses, occasional achiness and substantial hormone/GLP-1/GHK-Cu co-use.Sermorelin 1–29, not GHRH 1–44. Unverified products, self-report and heavy co-use; included only to show why analogue experiences cannot populate the parent molecule's felt clock.
Other context in this card
- Corpas et al. — Continuous subcutaneous infusions of GHRH 1-44 for 14 days in old men (opens in a new tab)PubMed abstract: healthy old men received randomized 1 and 2 mg/day continuous SC GHRH(1–44) for 14 days with a 14-day treatment-free period; 24-hour GH and IGF-I endpoints were measured.Continuous infusion and endocrine endpoints, not bolus PK, cosmetic effects or a gray-market community schedule.
What people say
- Body-comp talk (forums): Grouped with other GHRH agents for lean mass, recovery, and “anti-aging GH axis” goals — few logs isolate unmodified 1–44 from sermorelin / CJC / tesamorelin. forum
- Sleep / recovery adjacency: Sleep-depth and recovery anecdotes that appear under “GHRH” almost always map to bedtime sermorelin or CJC ± GHRP protocols, not pure full-length 1–44 logs. forum
- Honest sparsity: Lifestyle volume sits overwhelmingly on sermorelin, tesamorelin (esp. VAT lore), and CJC ± ipamorelin; unmodified “GHRH 1-44” is more a molecular parent / diagnostic name than a high-traffic solo stack. forum
- Endogenous GH framing: Discussed as amplifying the body’s own pulsatile GH rather than replacing GH with exogenous somatropin — feedback (somatostatin) still limits runaway exposure in theory. forum
- Diagnostics: IV GHRH / somatorelin stimulation tests (alone or with arginine) probe pituitary GH reserve with timed serial blood draws; used when intact somatotrophs need to be distinguished from hypothalamic failure. trial
- Elderly continuous-infusion signal (Corpas 1993): Continuous SC GHRH 1–44 at 1 mg/day and 2 mg/day for 14 days in healthy old men raised mean 24-h GH, GH peak number, and serum IGF-I toward young-adult-like patterns (daytime secretion particularly increased). trial
- Postmenopausal SC composition/performance (Veldhuis et al. 2005): Recombinant human GHRH-1,44-amide 1 mg SC twice daily for 3 months raised overnight GH ~98%, sustained IGF-I ~71% from week 2 onward, cut abdominal visceral fat ~16%, increased body water space ~14%, and improved selected performance measures (30 m walk, two-flight stair climb). trial
- Older-men body-comp adjacency: Same research line reported that high-dose twice-daily recombinant GHRH-1,44-amide for ~90 days altered body composition in healthy older men (visceral fat / performance narrative mirrored in the women’s follow-up). trial
- Program-level elderly exploration (Ehlers 2001 review context): Recombinant hGHRH(1–44)NH2 was discussed for chronic SC dose-ranging in elderly subjects with interest areas including body composition/function, osteoporosis adjacency, and congestive heart failure exploration — early-phase therapeutic-development framing, not a modern consumer product. trial
Doses people talk about
- Lifestyle mcg talk (sparse): Dedicated “GHRH 1-44” gray-market charts are uncommon; when people discuss it they often borrow sermorelin-like ~200–300 mcg bedtime SC patterns or abandon native 1–44 for Mod GRF / CJC / tesamorelin. forum
- Sermorelin reference band (related 1–29, not 1–44): Community/clinic wellness charts often cite ~100–500 mcg SC nightly (modal ~200–300 mcg) for sermorelin — useful as class context, not validated 1–44 dosing. forum
- Frequency logic for native form: Short plasma life → frequent pulses (multi-daily SC), continuous SC infusion in research, or switch to DPP-IV–resistant / albumin-binding analogs — not weekly depot logic. forum
- Empty-stomach / bedtime borrow: Night / pre-sleep and post-meal spacing habits are borrowed from broader GHRH (sermorelin/CJC) threads aiming at the nocturnal GH window; native 1–44–specific timing trials for lifestyle use are thin. forum
- Vendor uncertainty: Research-chem “GHRH 1-44” labels may vary on amidation, salt form, exact sequence length (1–40 vs 1–44 mix-ups), and purity without third-party tests. forum
- Diagnostic IV bolus (standard): ~1 µg/kg body weight GHRH/somatorelin as a single IV bolus is the widely cited stim-test dose in adults and children. trial
- Diagnostic max caps discussed: Some protocols cap at ~50 µg; others list a maximum around ~100 µg with the 1 µg/kg rule (e.g. GHRH-arginine service protocols naming Somatorelin/Ferring). trial
- Diagnostic sampling window: Serial GH draws commonly at baseline then ~15, 30, 45, 60, 90, and 120 minutes (exact grids vary by lab). trial
- GHRH + arginine combo test: GHRH ~1 µg/kg IV at time 0 plus arginine ~0.5 g/kg IV over ~30 minutes (arginine often capped ~30 g) — BMI-dependent peak-GH cutoffs used for adult GHD interpretation. trial
- Route bioavailability lesson (related analog): For a GHRH(1–29) analog, roughly ~10× higher SC than IV dose was needed for comparable GH stimulation; intranasal needed still higher relative doses for weaker GH release — full-length 1–44 shares the same “IV is potent, SC needs more peptide” practical lesson. trial
- Chronic SC research — continuous infusion (Corpas 1993): 1 mg/day and 2 mg/day continuous subcutaneous GHRH 1–44 infusions for 14 days in healthy old men (crossover with 14-day washout between doses). trial
- Chronic SC research — BID boluses (Veldhuis 2005 women): 1 mg recombinant human GHRH-1,44-amide SC twice daily (~2 mg/day total) for 3 months in postmenopausal volunteers. trial
- Chronic SC research — older men adjacency: Same high-dose twice-daily recombinant GHRH-1,44-amide approach for ~90 days reported in the related older-men body-composition line preceding the women’s study. trial
- Unit reality check: Published composition studies used milligram SC doses (e.g. 1 mg BID), not the ~100–300 mcg nightly bands common for compounded sermorelin wellness charts — do not conflate research mg regimens with forum mcg copy-paste. trial
- Framing: Numbers below are diagnostic protocols, published research regimens, and sparse community borrowing from related GHRH peptides — not advice, not prescriptions, not lifestyle protocols. forum
- Tesamorelin reference (modified 1–44, not native): FDA-era visceral-fat indication dosing is ~2 mg SC once daily for the original product (reformulated SV/WR labels are bioequivalent lower milligram presentations) — different molecule with DPP-IV-resistant N-terminal chemistry. trial
How it may feel
- Days 1–7 (lifestyle talk): Sparse pure-1–44 logs; if sleep/diet already solid, many report little distinctive subjective feel and quickly question practicality vs longer-lived analogs. forum
- Weeks 3–4: Sleep/recovery anecdotes remain hard to pin on unmodified 1–44 alone because stacks, training, and sleep hygiene confound. anecdote
- Post-stop: Washout logs specific to unmodified 1–44 are thin; class talk expects GH/IGF-1 driven effects to fade over days–weeks after short-acting peptides stop, with VAT benefits historically reversing after related GHRH-analog discontinuation (tesamorelin literature). forum
- Acute diagnostic IV window: Flushing/warmth and brief vasomotor sensations near the bolus and early sampling times are the classic supervised-test experience; some protocols also note transient metallic or odd taste. trial
- Minutes after SC research doses: Related short GHRH peptides often show GH rise within ~10 minutes SC with peak GH within ~30 minutes and return toward baseline by ~2 hours in analog route studies — users should not expect a long “on” feel from native full-length. trial
- Weeks 1–2: IGF-I can already be rising in supervised multi-milligram SC regimens (women’s study showed sustained IGF-I elevation from ~2 weeks); forum microgram-copy protocols are not the same exposure. trial
- Months 2–3: Composition and performance endpoints in clinical SC work land in this window (e.g. 3-month visceral fat and walk/stair measures at 1 mg BID). trial
- Local skin over multi-month high-dose SC: In the postmenopausal 1 mg BID study, most subjects (~70%) experienced local skin reactivity — a practical tolerability signal at research milligram doses. trial
Cycles people discuss
- Lifestyle calendars: On/off templates (e.g. 5 nights on / 2 off, multi-month on with lab checks) almost always belong to sermorelin, CJC ± ipamorelin, or tesamorelin discussions — not native 1–44–specific RCTs. forum
- Pulsed vs continuous: Short half-life favors frequent discrete pulses or continuous delivery; weekly “DAC-style” calendars do not map to unmodified 1–44. forum
- Diagnostic use: Single-session supervised stim test — not a multi-week “cycle.” trial
- Short research blocks: ~14-day continuous SC infusion courses with intervening washout in elderly GH/IGF-I restoration work. trial
- Multi-month research blocks: ~3-month (≈90-day) supervised high-dose SC courses for composition/performance endpoints in older adults. trial
- Duration honesty: No large modern wellness RCT defines an evidence-based lifestyle on/off schedule for unmodified full-length GHRH. trial
Timing
- Downstream timeline: Peptide clears in minutes; the GH pulse peaks on a tens-of-minutes scale; IGF-1 elevation and composition changes reflect multi-day to multi-month axis activity, not the peptide’s own half-life. forum
- Timing culture: Bedtime / pre-sleep SC patterns are borrowed from broader GHRH threads to align with natural nocturnal GH; multi-daily schedules appeared in milligram research (e.g. BID). forum
- Route note: IV diagnostic boluses are clinic-only; lifestyle discussion is almost entirely subcutaneous research vials — oral native GHRH is not a serious bioavailability path in community practice. forum
- Parent GHRH(1–44) after IV: In normal human volunteers, HPLC measured a 6.8-minute half-life for intact GRH(1–44)-NH2 after IV injection. That exact parent, route and assay should not be merged with endogenous GHRH, 1–29 fragments or stabilized analogs. trial
- In-vitro human plasma detail: HPLC measured about 17 minutes for intact GRH(1–44)-NH2, while total immunoreactivity by RIA lasted about 63 minutes because a stable but nearly inactive GRH(3–44) fragment remained detectable. Assay and analyte explain the difference. trial
- Primary degradation path: DPP-IV cleaves the N-terminal Tyr-Ala dipeptide (producing inactive/less-active 3–44 fragments); trypsin-like enzymes also cut (e.g. Arg11–Lys12 region on full-length sequences). trial
- Why analogs exist: Sermorelin (1–29) keeps the active core but stays short-acting; tesamorelin adds N-terminal hexenoyl chemistry on a 1–44 backbone for better stability; CJC no-DAC / Mod GRF adds substitutions (e.g. position-2 resistance talk); CJC with DAC adds albumin binding for multi-day half-life lore. trial
More on what it is
- What it is: Full-length 44–amino-acid human growth hormone–releasing hormone, often as the C-terminal amide GHRH(1-44)NH2; diagnostic/clinical name somatorelin; endogenous form sometimes called somatocrinin in older literature. trial
- What it does: Hits pituitary GHRH receptors → short endogenous GH pulse → downstream hepatic IGF-1; it is not injecting recombinant GH itself. trial
- Why the name matters: Parent molecule of the practical analogs people actually buy for lifestyle use — sermorelin is the active N-terminal 1–29 fragment; tesamorelin is a stabilized modified 1–44; CJC-class peptides are further engineered 1–29 derivatives. trial
- Why analogs dominate forums: Native full-length peptide is rapidly degraded by plasma peptidases (notably DPP-IV at the N-terminus, plus trypsin-like cleavage), so practical half-life is measured in minutes and multi-times-daily or continuous delivery was needed in research. trial
- Evidence posture: Solid diagnostic IV stim-test literature; multi-week to multi-month supervised SC recombinant hGHRH(1–44) work in older adults (GH/IGF-1, visceral fat, performance); very sparse dedicated gray-market “GHRH 1-44 only” bodybuilding logs. trial
- What it is not: Not hGH/somatropin, not a GHRP/ghrelin-mimetic, not tesamorelin (hexenoyl-modified 1–44), not sermorelin (1–29), not CJC-1295 with or without DAC. trial
- Potency note: Clinical comparisons historically treated natural GHRH(1–44)-NH2, GHRH(1–40)-OH, and truncated GHRH(1–29)-NH2 (sermorelin) as roughly equipotent for acute GH release when dose-matched — length alone is not “stronger GH.” trial
- 1–40 vs 1–44 detail: Some plasma-incubation work found GHRH(1–40) somewhat more peptidase-resistant than GHRH(1–44)NH2; both remain short-acting versus engineered analogs. trial
Stacks
- GHRH + GHRP dual pathway: Class stack pairs a GHRH agent with a ghrelin-receptor GHRP (ipamorelin preferred for lower hunger/cortisol lore; GHRP-2 and GHRP-6 still discussed) — native 1–44 is rarely the named GHRH half of modern logs. forum
- Analog swap (practical): Most users who start reading about full-length GHRH end on sermorelin or CJC (no-DAC or DAC) ± ipamorelin rather than chronic unmodified 1–44. forum
- Vs sermorelin for “physiologic pulse”: Sermorelin (1–29) carries the bulk of anti-aging clinic and forum pulse lore at mcg nightly doses; full-length 1–44 research often needed mg-scale SC exposure. forum
- Vs CJC-1295 DAC: DAC versions chase multi-day IGF-1 elevation and less frequent dosing; native 1–44 cannot mimic weekly depot logic. forum
- Basics confounders: Sleep, protein intake, resistance training, and calorie balance drive most composition outcomes and make solo-peptide attribution weak. forum
- Not typical repair stacks: BPC-157 / TB-500 / “Wolverine” cross-posts with pure 1–44 are rare and confounded when they appear. forum
- MK-677 adjacency: Oral ghrelin-mimetic sometimes compared as a non-inject GH-axis option; different receptor, different side profile (appetite, water, glucose lore) — not a GHRH. forum
- Vs tesamorelin for VAT: Tesamorelin is the modified 1–44 analog with dense HIV visceral-fat RCT data at ~2 mg daily; native 1–44 has smaller older-adult composition pilots, not the same label program. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection-site irritation: Redness, itching, swelling, or discomfort appear in community SC peptide handling — technique, volume, and product quality matter. forum
- GH-axis nonspecifics: Water retention, joint stiffness/aches, carpal-tunnel-like tingling, transient headache, and mild edema are discussed at the class level when GH/IGF-1 rise meaningfully. forum
- Glucose / insulin caution: Class-level talk that meaningful GH elevation can impair insulin sensitivity in susceptible people — relevant if labs or symptoms shift. forum
- Source / identity risk: Gray-market vials may be mislabeled relative to 1–29 fragments, 1–40, tesamorelin, or CJC products; no lifestyle safety database exists for unregulated full-length 1–44. forum
- Sparse AE database: Low pure-1–44 lifestyle volume means absence of forum horror stories is not evidence of safety. forum
- Cancer / IGF-1 theoretical caution: General GH/IGF-1 axis concern discussed across secretagogue communities when driving IGF-1 high long-term — evidence for unmodified 1–44 specifically is not a large surveillance program. forum
- Flushing (diagnostic IV): Transient facial flushing / warmth is classic during GHRH stim tests and related short GHRH peptide use. trial
- Taste change: Some stim-test and related-peptide reports note brief metallic or odd taste around dosing. trial
- Local skin reactivity (high-dose chronic SC): In the 1 mg BID × 3-month postmenopausal study, ~70% of subjects had local skin reactivity; no systemic adverse events were reported in that small open study — still a major practical tolerability flag at research milligram doses. trial
- Contrast with direct GH excess lore: High-dose rhGH literature lists hypertension, impaired glucose tolerance, salt/water retention, and carpal tunnel among serious concerns; secretagogue proponents argue preserved feedback may lessen that profile, but that is not proof native 1–44 is risk-free at high chronic SC doses. trial
- Diagnostic interpretation limits: GHRH-only tests can miss pure hypothalamic GHD (false reassurance if pituitary still fires); specialist protocols and BMI-aware cutoffs matter — DIY stim testing is not a substitute. trial
- Pregnancy / pediatric off-label: Not a community lifestyle use case; diagnostic pediatric contexts are specialist-only. trial
- WADA / sport: GHRH and analogs are prohibited growth-hormone releasing factors in sport anti-doping frameworks — relevant for tested athletes. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.